Barclays Maintains Equal-Weight on PTC Therapeutics, Lowers Price Target to $48
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Gena Wang maintains an Equal-Weight rating on PTC Therapeutics (NASDAQ:PTCT) and lowers the price target from $57 to $48.
May 24, 2023 | 10:28 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Barclays maintains an Equal-Weight rating on PTC Therapeutics and lowers the price target from $57 to $48.
The news directly mentions PTC Therapeutics (NASDAQ:PTCT) and the lowered price target by Barclays. This may cause short-term uncertainty among investors, but the Equal-Weight rating suggests that the stock is expected to perform in line with the market, resulting in a neutral short-term impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100